HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in Russia

CompletedOBSERVATIONAL
Enrollment

204

Participants

Timeline

Start Date

May 30, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Adenocarcinoma
Trial Locations (31)

Unknown

Research Site, Arkhangelsk

Research Site, Barnaul

Research Site, Belgorod

Research Site, Chelyabinsk

Research Site, Chita

Research Site, Grozny

Research Site, Irkutsk

Research Site, Kaluga

Research Site, Kemerovo

Research Site, Khabarovsk

Research Site, Khanty-Mansiysk

Research Site, Kostroma

Research Site, Krasnodar

Research Site, Krasnoyarsk

Research Site, Maykop

Research Site, Moscow

Research Site, Nizhny Novgorod

Research Site, Omsk

Research Site, Perm

Research Site, Ryazan

Research Site, Saint Petersburg

Research Site, Severodvinsk

Research Site, Sochi

Research Site, Surgut

Research Site, Tomsk

Research Site, Tver'

Research Site, Ufa

Research Site, Ulan-Ude

Research Site, Volgograd

Research Site, Yaroslavl

Research Site, Yuzhno-Sakhalinsk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY